<DOC>
	<DOCNO>NCT02379052</DOCNO>
	<brief_summary>The primary objective study assess clinical efficacy repeat subcutaneous ( SC ) dose dupilumab , compare placebo , relieve symptom adult patient active , moderate severe eosinophilic esophagitis ( EoE ) . The study comprise 2 section double-blinded , randomize , placebo-controlled study open label extension ( OLE ) evaluate long-term safety .</brief_summary>
	<brief_title>Study Dupilumab Adult Patients With Active Eosinophilic Esophagitis ( EoE )</brief_title>
	<detailed_description>This phase 2 , multicenter study consist : 1 ) double-blind , randomize , placebo-controlled study investigate efficacy , safety , tolerability , PK , immunogenicity dupilumab adult patient EoE , follow 2 ) OLE evaluate long-term safety . The study consist 4 period : screening , double-blind treatment ( without follow-up ) , OLE treatment , OLE follow-up . The maximum duration double-blind study approximately 33 week include screen follow-up . The expected duration OLE additional 2 year 12 week follow-up period .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Key inclusion criterion : 1 . Documented diagnosis EoE endoscopy prior screen 2 . History average least 2 episode dysphagia ( intake solid antiinflammatory therapy ) per week 4 week prior screen average least 2 episode document dysphagia per week week screen baseline ; dysphagia define trouble swallow solid food , solid food stick , patient report 3 . Must remain stabilized diet least 6 week prior screen course study ; stable diet define initiation single multiple elimination diet reintroduction previously eliminate food group 4 . Documented history presence following : allergic disease ( eg , allergic asthma , allergic rhinitis , AD , food allergy ) , peripheral eosinophil count ≥0.25 GI/L , serum total Immunoglobulin E ( IgE ) ≥100 kU/L 5 . Participation R688EE1324 clinical trial dupilumab EoE receive study treatment adequately complete assessment require least treatment period doubleblind study define protocol ( OLE ) . Key 1 . Prior participation dupilumab ( antiIL4R ) clinical trial 2 . Other cause esophageal eosinophilia follow disease : hypereosinophilic syndrome , ChurgStrauss vasculitis , eosinophilic gastroenteritis 3 . History achalasia , active Helicobacter pylorus infection , Crohn 's disease , ulcerative colitis , celiac disease , prior esophageal surgery prior screen 4 . Any esophageal stricture unable pass standard , diagnostic , adult ( 9 to10 mm ) upper endoscope critical esophageal stricture require dilation screen 5 . History bleed disorder esophageal varix 6 . Use chronic aspirin , nonsteroidal agent , anticoagulant within 2 week prior screen . Patients stop agent solely become eligible entry study 7 . Treatment investigational drug within 2 month within 5 halflives ( know ) , whichever longer , prior screen 8 . Use systemic corticosteroid within 3 month swallow topical corticosteroid within 3 month prior screen 9 . Use inhaled ( pulmonary nasal ) topical corticosteroid within 3 month prior screen study , except stable dose least 3 month prior screen biopsy , change study 10 . Treatment oral immunotherapy ( OIT ) within 6 month prior screen 11 . Allergen immunotherapy unless stable dose least 1 year prior screen 12 . Pregnant breastfeed woman , woman plan become pregnant breastfeed study 13 . Patients , participation previous dupilumab clinical trial , develop AE deem related dupilumab lead study treatment discontinuation ( OLE ) Note : The list inclusion/ exclusion criterion provide intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>